Skip to main content
Journal cover image

Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial.

Publication ,  Journal Article
McCall, WV; Lisanby, SH; Rosenquist, PB; Dooley, M; Husain, MM; Knapp, RG; Petrides, G; Rudorfer, MV; Young, RC; McClintock, SM; Mueller, M ...
Published in: J Psychiatr Res
February 2018

We examined whether electroconvulsive therapy (ECT) plus medications ("STABLE + PHARM" group) had superior HRQOL compared with medications alone ("PHARM" group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the "STABLE + PHARM" group versus the "PHARM" group. The overall study design was called "Prolonging Remission in Depressed Elderly" (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of "STABLE + PHARM" versus "PHARM". Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The "PHARM" group received venlafaxine and lithium. The "STABLE + PHARM" received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7%) with a mean age of 70.5 ± 7.2 years. "STABLE + PHARM" patients received 4.5 ± 2.5 ECT sessions during Phase 2. "STABLE + PHARM" group had 7 point advantage (3.5-10.4, 95% CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2-12.2, 95% CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. CLINICAL TRIALS.GOV: NCT01028508.

Duke Scholars

Published In

J Psychiatr Res

DOI

EISSN

1879-1379

Publication Date

February 2018

Volume

97

Start / End Page

65 / 69

Location

England

Related Subject Headings

  • Venlafaxine Hydrochloride
  • Secondary Prevention
  • Quality of Life
  • Psychiatry
  • Outcome Assessment, Health Care
  • Middle Aged
  • Male
  • Lithium Compounds
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
McCall, W. V., Lisanby, S. H., Rosenquist, P. B., Dooley, M., Husain, M. M., Knapp, R. G., … CORE/PRIDE Work Group. (2018). Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. J Psychiatr Res, 97, 65–69. https://doi.org/10.1016/j.jpsychires.2017.11.001
McCall, W Vaughn, Sarah H. Lisanby, Peter B. Rosenquist, Mary Dooley, Mustafa M. Husain, Rebecca G. Knapp, Georgios Petrides, et al. “Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial.J Psychiatr Res 97 (February 2018): 65–69. https://doi.org/10.1016/j.jpsychires.2017.11.001.
McCall WV, Lisanby SH, Rosenquist PB, Dooley M, Husain MM, Knapp RG, et al. Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. J Psychiatr Res. 2018 Feb;97:65–9.
McCall, W. Vaughn, et al. “Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial.J Psychiatr Res, vol. 97, Feb. 2018, pp. 65–69. Pubmed, doi:10.1016/j.jpsychires.2017.11.001.
McCall WV, Lisanby SH, Rosenquist PB, Dooley M, Husain MM, Knapp RG, Petrides G, Rudorfer MV, Young RC, McClintock SM, Mueller M, Prudic J, Greenberg RM, Weiner RD, Bailine SH, Youssef NA, McCloud L, Kellner CH, CORE/PRIDE Work Group. Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. J Psychiatr Res. 2018 Feb;97:65–69.
Journal cover image

Published In

J Psychiatr Res

DOI

EISSN

1879-1379

Publication Date

February 2018

Volume

97

Start / End Page

65 / 69

Location

England

Related Subject Headings

  • Venlafaxine Hydrochloride
  • Secondary Prevention
  • Quality of Life
  • Psychiatry
  • Outcome Assessment, Health Care
  • Middle Aged
  • Male
  • Lithium Compounds
  • Humans
  • Female